120 related articles for article (PubMed ID: 37741606)
1. Inhibition of PAK1 generates an ameliorative effect on MPLW515L mouse model of myeloproliferative neoplasms by regulating the differentiation and survival of megakaryocytes.
Fu C; Hu X; Wang S; Yu X; Zhang Q; Zhang L; Qi K; Li Z; Xu K
Exp Hematol; 2023 Nov; 127():59-69.e2. PubMed ID: 37741606
[TBL] [Abstract][Full Text] [Related]
2. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
3. [Construction of a Mouse Model for Myeloproliferative Neoplasms and an Evaluation System].
Wang SJ; Yu XR; Zhang QG; Li YJ; Fu CL; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1113-1118. PubMed ID: 37551485
[TBL] [Abstract][Full Text] [Related]
4. AKT is a therapeutic target in myeloproliferative neoplasms.
Khan I; Huang Z; Wen Q; Stankiewicz MJ; Gilles L; Goldenson B; Schultz R; Diebold L; Gurbuxani S; Finke CM; Lasho TL; Koppikar P; Pardanani A; Stein B; Altman JK; Levine RL; Tefferi A; Crispino JD
Leukemia; 2013 Sep; 27(9):1882-90. PubMed ID: 23748344
[TBL] [Abstract][Full Text] [Related]
5. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
6. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
Zhang Y; Lin CHS; Kaushansky K; Zhan H
Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
[TBL] [Abstract][Full Text] [Related]
7. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
[TBL] [Abstract][Full Text] [Related]
8. Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.
Malherbe JA; Fuller KA; Arshad A; Nangalia J; Romeo G; Hall SL; Meehan KS; Guo B; Howman R; Erber WN
J Clin Pathol; 2016 Feb; 69(2):155-63. PubMed ID: 26290261
[TBL] [Abstract][Full Text] [Related]
9. [Blocking PAK1 kinase activity promotes the differentiation of acute megakaryocytic leukemia cells and induces their apoptosis].
Wang SJ; Wang CQ; Hu XT; Yu XR; Fu CL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):499-505. PubMed ID: 35968594
[No Abstract] [Full Text] [Related]
10. PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms.
Li Y; Gao H; Dong H; Wang W; Xu Z; Wang G; Liu Y; Wang H; Ju W; Qiao J; Xu K; Fu C; Zeng L
Biochem Pharmacol; 2022 May; 199():115013. PubMed ID: 35318038
[TBL] [Abstract][Full Text] [Related]
11. JAK2
Zhan H; Ma Y; Lin CH; Kaushansky K
Leukemia; 2016 Dec; 30(12):2332-2341. PubMed ID: 27133820
[TBL] [Abstract][Full Text] [Related]
12. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
Yue L; Sharma V; Horvat NP; Akuffo AA; Beatty MS; Murdun C; Colin C; Billington JMR; Goodheart WE; Sahakian E; Zhang L; Powers JJ; Amin NE; Lambert-Showers QT; Darville LN; Pinilla-Ibarz J; Reuther GW; Wright KL; Conti C; Lee JY; Zheng X; Ng PY; Martin MW; Marshall CG; Koomen JM; Levine RL; Verma A; Grimes HL; Sotomayor EM; Shao Z; Epling-Burnette PK
Blood; 2020 Jan; 135(3):191-207. PubMed ID: 31750881
[TBL] [Abstract][Full Text] [Related]
13. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer.
Yeo D; Phillips P; Baldwin GS; He H; Nikfarjam M
Int J Cancer; 2017 May; 140(9):2101-2111. PubMed ID: 28109008
[TBL] [Abstract][Full Text] [Related]
16. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
Tabusa H; Brooks T; Massey AJ
Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
[TBL] [Abstract][Full Text] [Related]
18. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
19. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.
Zhu Y; Liu H; Xu L; An H; Liu W; Liu Y; Lin Z; Xu J
Cell Death Dis; 2015 Feb; 6(2):e1637. PubMed ID: 25675297
[TBL] [Abstract][Full Text] [Related]
20. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
Balduini A; Badalucco S; Pugliano MT; Baev D; De Silvestri A; Cattaneo M; Rosti V; Barosi G
PLoS One; 2011; 6(6):e21015. PubMed ID: 21698292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
